27 | Sep | 2020
What's New
01 | Sep | 2020
We are pleased to welcome Ted Ira to the Biomere team as Head of Sales and Business Development!
“I’m excited to join such an innovative, knowledgeable, and experienced contract research team. Biomere’s 25 year successful track record in the CRO industry is a strong foundation upon which to introduce their newest site in the San Francisco Bay Area. Together with their labs outside of Boston, GLP capabilities in China, and a focus on putting the customer needs first, Biomere is truly positioned to provide a unique option to help advance drug discovery and development.”
Ted joins Biomere from Vium where he led the market launch of a digital vivarium platform used by biotech, pharmaceutical, and academic institutions to transform in vivo research. He has held various sales and business development positions with pre-clinical, clinical, and technology innovation industry leaders.
Ted’s extensive commercial, technical, and customer partnership background makes him the perfect fit for Biomere’s culture of quality and responsiveness.
Welcome Ted!
28 | Aug | 2020
JOINN is proud to announce its 25th anniversary!
Since the establishment of the business on August 25, 1995 as the first private, non-clinical CRO in China, JOINN has been focusing on the objective of “Providing exceptional services for drug innovation, ultimately for the benefit of mankind.” After 25 years of dedication and hard work from our members, JOINN has built a solid reputation within the industry, becoming the largest CRO for safety assessment in China, while progressively expanding our services to clinical CRO, pharmacovigilance and research model services.
Coincidently, it is also August 25th that JOINN became a listed company and the stock went public on SSE in the China A stock market in 2017. Since then, the market capitalization of JOINN has reached 2.85B U.S. Dollars. Currently there are 1,200 employees serving the company, as well as a total of six facilities in both the U.S. and China, five which are in operation and one in construction.
Since 2019, JOINN increased its global footprint by merging with Biomere and launching new laboratories in California. With Biomere joining the family, we are looking forward to achieving great synergy. Based on the natural fit between Biomere and JOINN, the company will leverage Biomere’s well-established reputation promoting cooperation of industry experts from both sides, aiming for expansion throughout not only the east and west coast, but eventually the east (China) and the west (US).
With JOINN and Biomere’s integration, we should be confident that the company will continue to thrive, relying on the effort and support from each member.
We are ready for another 25 years!
Daniel Gao
August 25, 2020
12 | May | 2020
No Patient Left Behind
Many of the world’s biggest companies and brightest minds are totally focused on a COVID-19 treatment – vaccine.
At Biomere, we are personally invested in your drug discovery efforts aimed at filling the drug development pipeline with new and innovative therapies.
Everyone has a role to play and we know ours. We are staying the course, focused on what we do best.
Leave no drug behind. Leave no patient behind.
27 | Apr | 2020
No Drug Left Behind
We are personally invested in your efforts to continue the flow of therapies to those in need. Some of the worlds’ best companies are totally focused on a treatment – vaccine.
Everyone has a role to play and we know where ours is. No less important, but not working on COVID-19. We are staying on course, focused on what we do best.
Leave no drug behind. Leave no patient behind.
24 | Mar | 2020
COVID-19 Vaccine Receives Approval in China to Begin Human Trials
March 22, 2020 —A recombinant novel coronavirus vaccine candidate (Ad5-nCoV), developed by CanSino Biologics Inc. and China’s Academy of Military Medical Sciences, received Chinese regulatory approval to start human trials against COVID-19 on March 22, 2020
Results from preclinical animal studies of Ad5-nCoV show that the vaccine candidate induces strong immune responses in animal models. Preclinical animal safety studies demonstrate a good safety profile supporting clinical development. Multiple vaccines for the novel coronavirus (COVID-19) are expected to complete preclinical research in April and enter clinical trials in China, NMPA officials declared at a press conference on March 17, 2020.
In response to the outbreak of coronavirus (COVID-19), JOINN assembled a team of internal experts to develop study designs tailored to evaluate different types of novel therapies against COVID-19. We have established clinical sample analysis centers in Wuhan to support clinical trials. JOINN participated in the safety assessment of most anti-SARS-CoV-2 drugs in China, including DNA vaccines, mRNA vaccines, recombinant protein-based vaccines, peptide vaccines, inactivated virus vaccines and other drugs such as antibodies, stem-cell therapy drugs, etc. Most drugs are still in the pre-clinical stage, some have already been submitted to the regulatory department of the NMPA (National Medical Products Administration) of China.
About Joinn
Founded in 1995, JOINN Laboratories (JOINN, SH603127) is China’s first private nonclinical CRO. JOINN subsidiaries are located in Beijing, Suzhou, Chongqing, and Wuzhou (GuangXi Province) in China, and Richmond (CA) and Worcester (MA) in the United States. JOINN is CNAS/ILAC-MRA accredited (China National Accreditation Service for Conformity Assessment/International Laboratory Accreditation Cooperation-Mutual Recognition Arrangement), AAALAC accredited (Association for Assessment & Accreditation of Lab Animal Care International) and OLAW accredited, and is NMPA (CFDA), US FDA, OECD and Ko-rean MFDS GLP certified/inspected/compliant. JOINN employs 1500+ pharmaceutical professionals and provides services from early-stage R&D to clinical trials and to post-approval pharmacovigilance, tailored to the sponsor’s needs.
JOINN has extensive experience on anti-virus drug safety assessment. We have participated in the drug R & D and safety assessment of SARS, H5N1, H1N1, H7N9 and Ebola virus. In response to the outbreak of coronavirus (COVID-19), JOINN developed a green channel for rapid response to antivirus non-clinical and clinical requests. We can help sponsors to communicate with local regulatory authorities, accelerating antivirus therapy development.
For the full report with language translation, see here.
